GLP-1受体激动剂对代谢重编程和心脏保护的协同作用
Xuan Wang1, Mengmeng Qi1, Lili Yang1
1Department of Endocrinology and Metabolism, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Frontiers in endocrinology
|October 29, 2025
概括
类似葡萄糖类-1受体激动剂 (GLP-1RAs) 通过重编程心脏新陈代谢,在糖尿病中提供心血管保护. 这涉及优化能量利用和减少氧化应激,这对于糖尿病患者的心脏病管理至关重要.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 糖尿病明显增加了心血管疾病 (CVD) 的风险和死亡率.
- 类似葡萄糖-1受体激动剂 (GLP-1RAs) 在治疗糖尿病和心血管疾病方面表现有前途.
- 代谢重编程正在成为GLP-1RA心脏保护的关键机制.
研究的目的:
- 在正常和糖尿病状态下审查心脏能量代谢.
- 阐明代谢重编程在GLP-1RA介导心脏保护中的作用.
- 讨论使用GLP-1RAs准代谢途径的治疗潜力和挑战.
主要方法:
- 关于GLP-1RAs,心脏代谢和糖尿病的研究文献综述.
- 通过GLP-1RAs影响脂肪酸,葡萄糖和体代谢的机制的分析.
- 检查GLP-1RA对线粒体功能和心脏中氧化应激的影响.
主要成果:
- GLP-1RAs调节关键的代谢途径,包括脂肪酸氧化和葡萄糖利用.
- 这些药物增强了线粒体的效率,并减少了心脏细胞中反应性氧物种的产生.
- GLP-1RAs的代谢重编程优化了心脏能量恒温,减轻了糖尿病心肌病.
结论:
- 代谢重编程是GLP-1RAs对心血管的益处的一个关键机制.
- 准心脏新陈代谢为糖尿病心脏病提供了一个有前途的治疗策略.
- 需要进一步的研究来优化GLP-1RA疗法并克服临床挑战.
相关概念视频
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
GPCRs Regulate Adenylyl Cylase Activity
7.3K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
7.3K
Dipeptidyl Peptidase 4 Inhibitors
575
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
575
Oral Hypoglycemic Agents: Biguanides and Glitazones
581
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
581
Global Regulatory Systems
593
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
593
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K


